Welcome to our dedicated page for Alkermes Plc news (Ticker: ALKS), a resource for investors and traders seeking the latest updates and insights on Alkermes Plc stock.
Alkermes plc (ALKS) is a leading neuroscience-focused biopharmaceutical company developing innovative therapies for central nervous system disorders. This page provides investors and industry observers with direct access to official company announcements, including regulatory milestones, clinical trial developments, and strategic business updates.
Our curated collection features Alkermes' latest press releases on FDA submissions, partnership agreements, and financial results. Users will find updates on key therapeutic areas such as schizophrenia treatments, narcolepsy research, and bipolar disorder therapies. The archive also includes manufacturing expansions and peer-reviewed study publications.
Bookmark this page for real-time updates on ALKS' neuroscience pipeline progress, quarterly earnings disclosures, and corporate governance announcements. Check regularly for new developments in the company’s clinical programs and commercial product portfolio.
Alkermes revealed data from a Phase 1b study of ALKS 2680, a novel orexin 2 receptor agonist, showing significant improvements in wakefulness in patients with narcolepsy type 1 (NT1). The study, presented at SLEEP 2024, demonstrated that ALKS 2680 significantly improved mean sleep latency compared to placebo across all doses. The drug was well-tolerated, with most adverse events being mild and transient. Additionally, the ongoing Phase 2 Vibrance-1 study will further evaluate the efficacy and safety of ALKS 2680 in NT1 patients. Initial results are encouraging, highlighting the potential of ALKS 2680 to address unmet needs in NT1 treatment.
Alkermes (Nasdaq: ALKS) announced its participation in two upcoming investor conferences. Management will present at the Jefferies Healthcare Conference on June 6, 2024, at 1:30 p.m. EDT and at the Goldman Sachs 45th Annual Global Healthcare Conference on June 11, 2024, at 10:40 a.m. EDT. The presentations will be webcast live and available under the Investors tab on Alkermes' website for 14 days. Alkermes is a biopharmaceutical company with a portfolio targeting alcohol and opioid dependence, schizophrenia, and bipolar I disorder, along with a pipeline for neurological disorders.
Alkermes announced plans to present three posters on ALKS 2680, a novel, investigational, oral orexin 2 receptor agonist, at SLEEP 2024, June 1-5 in Houston.
Key presentations include:
- Data from a phase 1b study of ALKS 2680 in narcolepsy type 1 (NT1) patients, evaluating safety and efficacy.
- Study design and methods for the Vibrance-1 phase 2 trial comparing ALKS 2680 with placebo in NT1 patients.
- Findings from interviews on the impact of narcolepsy on patients' lives.
Significant progress has been noted in the ALKS 2680 program, with proof-of-concept data validating the design hypothesis and initiating the Vibrance-1 phase 2 study.
Alkermes (Nasdaq: ALKS) announced the presentation of research related to its psychiatry franchise products, LYBALVI and ARISTADA, at four scientific conferences in Spring 2024. These conferences, held during Mental Health Awareness Month, include events like the APA Annual Meeting and ASCP Annual Meeting.
Key highlights include results from a long-term phase 3 study on LYBALVI's safety and efficacy and insights from healthcare resource utilization studies on ARISTADA. Alkermes aims to advance understanding and evidence for their psychiatric treatments targeting schizophrenia and bipolar I disorder.
Alkermes plc has completed the sale of its development and manufacturing facility in Athlone, Ireland to Novo Nordisk for approximately $91 million. The sale is part of Alkermes' program to drive operational efficiency and align its infrastructure with business needs. The transaction includes a subcontracting agreement with Novo Nordisk until the end of 2025, expected to be cost-neutral to Alkermes. Post-subcontracting, the sale is anticipated to provide significant operating cost benefits and enhance profitability. Alkermes will retain royalty revenues from products manufactured at the facility while continuing to produce its commercial products in Ohio.
Alkermes plc reported first-quarter 2024 financial results with revenues of $350.4 million, GAAP net income of $38.9 million, and diluted GAAP earnings per share of $0.23. They reiterated their 2024 financial expectations. The company highlighted prescription growth for LYBALVI® and progress with ALKS 2680 for narcolepsy treatment. Key financial highlights include total revenues, profitability, revenue growth for LYBALVI, ARISTADAi, VIVITROL, and royalty revenues. Operating expenses saw an increase due to investments. The company's balance sheet showed cash and total investments of $807.8 million. Alkermes confirmed its financial expectations for 2024 and recent events like new board member appointments, data presentations, and study initiations.
FAQ
What is the current stock price of Alkermes Plc (ALKS)?
What is the market cap of Alkermes Plc (ALKS)?
